Patients with heart failure and reduced ejection fraction after sacubitril/valsartan treatment may be at risk for major adverse cardiovascular events according to ΔRDW.

Authors

  • Shashi Bhusan Sutar, Jitendra Naik, Gouri Oram, Desabandhu Behera Author

DOI:

https://doi.org/10.48047/

Keywords:

distribution width of red blood cells, heart failure with reduced ejection fraction, major adverse cardiovascular events, sacubitril, valsartan

Abstract

The objective of this study was to assess the correlation between alterations in the distribution 
width of red blood cells (RDW) and the incidence of major adverse cardiovascular events 
(MACEs) in patients with heart failure with reduced ejection fraction (HFRF) receiving 
sacubitril/valsartan therapy.

Downloads

Download data is not yet available.

Downloads

Published

2024-03-01

Issue

Vol. 15 No. 3 (2024): volume 15 issue 3 (2024)

Section

Articles